CGTN
19.8.2020 14:12:04 CEST | Business Wire | Press release
Chinese President Xi Jinping arrived in east China's Anhui Province for an inspection tour on Tuesday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005372/en/
Xi, also general secretary of the Communist Party of China Central Committee, visited the floodgate of the Wangjiaba Dam on the Huaihe River and other flood-hit areas in Funan County, Fuyang City. He also went to a "zhuangtai," a residential structure built on raised ground at a higher elevation that functions as a haven from river floods.
Since June, Anhui has been ravaged by floods and landslides caused by incessant heavy rains.
The president also met with local officials and residents and learned about flood prevention and disaster relief work and the progress of recovery efforts.
This is President Xi's latest inspection tour this year, following his visits to Yunnan Province , Beijing Municipality , Hubei Province , Zhejiang Province , Shaanxi Province , Shanxi Province , Ningxia Hui Autonomous Region and Jilin Province .
People-centered efforts
"I have always been concerned about the people in flood-stricken areas," Xi said while meeting locals, adding that he felt ease after seeing villagers had a place to live and had restarted production.
Severe rainstorms have hit many regions in China this summer, triggering flooding of rivers. According to the Ministry of Emergency Management (MEM), 54.8 million people in 27 provincial-level regions have been affected.
Chinese leaders have called for unrelenting efforts to ensure the safety of people's lives and property.
During a CPC leadership meeting on July 17, President Xi stressed putting people's lives and property first and taking more forceful measures to do well in flood control and relief work.
China has made all-out efforts in flood control and disaster relief with massive mobilization, evacuations and a top-level emergency response in several hard-hit provinces.
Through the nationwide joint efforts, the MEM said, the number of deaths and missing due to floods fell by 53.9 percent from with the national average of the past five years. The number of evacuated people increased by 36.7 percent, the ministry added.
Enhance capabilities to cope with natural disasters
Noting that China has fought against natural disasters for thousands of years, Xi on Tuesday also urged respect for nature, harmony between humans and nature and efforts to improve capabilities to cope with natural disasters.
"We should modernize our ability to prevent and combat natural disasters in our effort to build a modern socialist country in an all-round way," Xi added.
Hailed as the "most important floodgate on the Huaihe River," the floodgate of the Wangjiaba Dam sets a good example of China's flood preparation.
The floodgate, built in 1953 was opened for the 16th time on July 20 to store water, intercepting 375 million cubic meters of potential floodwater by July 23 when it was closed.
The CPC leadership meeting on July 17 also stressed that China needs to comprehensively enhance its disaster prevention capability and will include capacity building on disaster prevention in its 14th Five-Year Plan covering the period 2021-2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200819005372/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
